On our screens:Cheap stocks by free cash flow yield
Is the price fair?
What PGNY's price assumes
Progyny, Inc. trades at 35.3× earnings against 25.6× for the median Healthcare Plans name, more expensive than its own group.
35.3
Trailing P/E · Healthcare Plans median 25.6 · 1.38× the median: the market pays up for this one
- Price / sales
- 1.11
Price / sales · as of 2026-Q1
- Free cash flow yield
- 8.6%
Free cash flow yield · Healthcare Plans median 6.5%
- Growth the price implies
- −1.6%
Growth the price implies · The price pays for −1.6% free cash flow growth a year for a decade; the business has delivered +19% a year over the last three.
Details›
- Price / book2026-Q1
- 3.28
- Healthcare median P/E362 names
- 29.9
- Healthcare Plans median P/E11 names
- 25.6
- Free cash flow, trailing twelve months
- $184M
- Market capitalisation
- $2.14B
- 3-year revenue growth
- +14%
- 3-year free cash flow growth
- +19%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 33.3× today against a 73.0× median |
| 52-week range | $16.30 – $32.37 |
| Today | $27.15 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.